| Co-expression
of MAGEC1 and NY-ESO-1 in cancer cell lines and
primary tumors.
| Samples |
No. of Samples Expressing |
No.
of Samples Expressing MAGEC1 and NY-ESO-1 |
| MAGEC1 |
NY-ESO-1 |
| Cancer
cell lines (n = 88) |
42
(48%) |
38
(43%) |
28
(32%) a |
| Multiple
myeloma (n = 39) |
30 (77%) |
13 (33%) |
10 (26%) |
| NSCLC
(n = 456) |
101 (22%) |
120 (26%) |
59 (13%) b |
aUsing
the chi-squared test, co-expression of MAGEC1 and NY-ESO-1
is significantly higher (P < 0.0001) than would be expected
if these two genes associated independently based on their individual
expression frequency.
bUsing Cohen’s kappa measure, the association
of MAGEC1 and NY-ESO-1 expression is fair (κ
= 0.38), indicating that agreement is greater than one would expect
by chance (P < 0.0001). The kappa test was only performed
for non-small cell lung cancer (NSCLC) samples.
|
